[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Medivators, Inc.\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":58},{"warningLetters":4,"total":57},[5,31],{"id":6,"raw":7,"subject":14,"body_html":15,"body_text":16,"firm_name":17,"letter_id":18,"created_at":19,"fei_number":20,"letter_url":21,"updated_at":22,"action_type":23,"case_status":24,"posted_date":25,"marcs_cms_no":26,"product_type":27,"closeout_date":20,"issuing_office":11,"recipient_name":28,"body_fetched_at":29,"delivery_method":20,"recipient_title":20,"reference_number":20,"action_taken_date":30,"medical_device_id":20,"response_letter_date":20},2119,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2023-04-25T13:20:00Z\">04\u002F25\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-02-13T05:00:00Z\">02\u002F13\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmedivance-instruments-ltd-647562-02132023\">Medivance Instruments Ltd.\u003C\u002Fa>","Center for Devices and Radiological Health","Medical Device\u002FAdulterated\u002FMisbranded\u002FLacks PMA and\u002For 510(k)\u003Cbr \u002F>\r\n","","Medical Device\u002FAdulterated\u002FMisbranded\u002FLacks PMA and\u002For 510(k)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Sidney Grant\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Managing Director, CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Medivance Instruments Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Barretts Green Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Harlesden\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>London\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>NW10 7AE\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United Kingdom\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>February 13, 2023\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Grant:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located in Harlesden, London, United Kingdom on August 8, 2022, through August 11, 2022, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures the Velopex Aquacut Fluid Abrasion Unit (“Velopex Device”) and various accessories as part of the Velopex AquaCare Dental Abrasion line of products. These products are intended for use in a range of dental procedures, including sealant preparation, composite removal and restoration, and cavity preparation. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\n\n\u003Cp>We received a response from you dated September 1, 2022, concerning our investigator’s observations noted on the Form FDA 483 (“FDA 483”), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>Your firm currently holds a 510(k) clearance (K024105) for the Velopex Device, which was issued on October 9, 2003. However, since the time it was cleared, the Velopex Device has been, in multiple ways, significantly changed or modified in design, components, method of manufacture, or intended use within the meaning of 21 CFR 807.81(a)(3). Specifically, your firm has made significant changes that include, among other things, the incorporation of a new air regulator and changes to the materials used in the powder tubing\u002Fvalves. Firm documents inspected by FDA noted that the incorporation of a new air regulator is intended to address the risk or reliability and pipe stress failure of the device by changing the parameters of the air flow and operating pressure range that are factory set. The changes to the air regulator may impact the ratio of the air\u002Fwater\u002Fpowder mixture that contacts the surface of the dentition and the efficiency of how that mixture moves through the system. Further, the changed powder tubing\u002Fvalve materials included a container molded insert and slide insider, which may impact the performance of the drip of the powder.\u003C\u002Fp>\n\n\u003Cp>The changes outlined in this warning letter and other changes could significantly affect the safety or effectiveness of the device within the meaning of 21 CFR 807.81(a)(3). Accordingly, your firm was required to submit a new premarket notification submission under section 510(k) of the Act, 21 U.S.C. § 360(k), to FDA at least 90 days before you proposed to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of the modified Velopex devices (“Modified Velopex Devices”). (See 21 CFR 807.81(a)(3).)\u003C\u002Fp>\n\n\u003Cp>You did not submit any new 510(k) in association with the Modified Velopex Devices. The Modified Velopex Devices are therefore misbranded under section 502(o) the Act, 21 U.S.C. §352(o), because your firm did not timely notify FDA of its intent to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of the Modified Velopex Devices, as required by section 510(k) of the Act.\u003C\u002Fp>\n\n\u003Cp>Our inspection revealed that the Modified Velopex Devices are also adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g).\u003C\u002Fp>\n\n\u003Cp>For a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm\">http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm\u003C\u002Fa>. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. These deficiencies include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to establish and maintain procedures for the identification, documentation, validation or where appropriate verification, review and approval of design changes before their implementation as required by 21 CFR 820.30(i). For example, your firm has not verified or validated design changes during and after your firm’s design and development process prior to implementation. Your firm also stated to FDA that certain design changes for your AquaCare devices, including the Aquacut and AquaCare Single and Twin devices, were validated but not adequately documented.\u003C\u002Fp>\n\n\u003Cp>The response dated 09\u002F01\u002F2022 is not adequate. Your firm identified its plan to revise its Design and Development procedure to meet the requirements of 21 CFR 820.30(i). Also, your firm states it plans to conduct effectiveness checks of these revised procedures. Your firm additionally provided red-lined portions of the current Design and Development procedure to describe the specific changes that were made to the procedure. However, your firm’s response failed to provide a plan on how it would retrospectively validate and, where appropriate, verify that the changes to its 510(k) cleared device were safe and effective for the device’s current intended use. Your response also failed to explain how your firm was going to establish and maintain procedures for the identification, documentation, validation (or, where appropriate, verification), review, and approval of design changes before their implementation on devices currently distributed in the US marketplace.\u003C\u002Fp>\n\n\u003Cp>2. Failure to establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). Your firm failed to conduct CAPA investigations and failed to verify the effectiveness of Corrective Actions taken as part of a CAPA, or indicate that verification was not required, as required by your firm’s corrective and preventive action (CAPA) procedure. For example, your firm’s corrective and preventive action (CAPA) procedure does not have a requirement to verify or validate corrective and\u002For preventive action for every CAPA activity. Upon review of thirty CAPA records from 2019to 2021 (including CAPAs 2019-1 to 2019-5, 2019-7 to 2019-16, 2020-1, 2020-2, and 2021-1 to 2021-13), it was observed that none of these records were evaluated for effectiveness. Further, some CAPA activity lacked corrective and\u002For preventive actions. Accordingly, your firm failed to verify or validate the effectiveness of CAPA actions to ensure the finished device was not adversely affected.\u003C\u002Fp>\n\n\u003Cp>The response dated 09\u002F01\u002F2022 is not adequate. Your firm identified its plan to revise its CAPA procedure, CAPA Request form and CAPA Log (and provided copies of these revised documents as part of your response) to meet the requirements of 21 CFR 820.100(a). Your firm also noted that staff would be trained on how to implement the updated CAPA procedure, form, and log. However, the firm’s plan did not describe how it planned to address currently outstanding CAPAs, nor provide a timeline on when it anticipated these outstanding CAPAs to be resolved.\u003C\u002Fp>\n\n\u003Cp>3. Failure to review and evaluate all complaints to determine whether an investigation is necessary. When no investigation is made, the manufacturer shall maintain a record that includes the reason no investigation was made and the name of the individual responsible for the decision not to investigate, as required by 21 CFR 820.198(b). For example, your Customer Complaints procedure states all customer complaints must be investigated and if rejected, a justification must be documented. During inspection, your firm stated to FDA that complaint investigations are carried out but might not have been documented. However, forty-eight customer complaints from 2019-2022 were reviewed where no investigation was performed, and a justification was not documented as to why no investigation was performed.\u003C\u002Fp>\n\n\u003Cp>The response dated 09\u002F01\u002F2022 is not adequate. Your firm identified its plan to revise its Customer Complaints procedure to meet the requirements of 21 CFR 820.198(b). Also, your firm has plans to revise the Customer Complaints Form; generate a new Faults Investigation form and retrain all required personnel. Your firm provided copies of the revised procedure, revised Customer Complaints form and a new Faults Investigation form as part of your investigation. Your firm has yet to complete personnel training. Although your firm’s plan indicates a commitment to resolve new complaints that you receive, it does not address a commitment and timeline to investigate and resolve current, pending complaints such as the ones identified as part of FDA’s investigation. Investigation and resolution of complaints is required per your firm’s revised SOP; which states in part that complaints shall be evaluated to determine whether a CAPA will be required, shall be conducted; and if required the QA\u002FRA department will be notified to coordinate initiation and resolution of the CAPA.\u003C\u002Fp>\n\n\u003Cp>4. Failure to maintain device history records (DHR's). Each manufacturer shall establish and maintain procedures to ensure that DHR's for each batch, lot, or unit are maintained to demonstrate that the device is manufactured in accordance with the device master record(DMR) and the requirements of this part, as required by 21 CFR 820.184. For example, your firm does not have procedures to ensure the DHR for each unit of your device is manufactured in accordance with the DMR and requirements of the regulation. Your firm does not have a DHR procedure. In addition, your firm’s device DHRs for your AquaCare device lacks identification labeling as well as a Unique Device Identifier (UDI) or Universal Product Code (UPC) for each device unit.\u003C\u002Fp>\n\n\u003Cp>The adequacy of the response dated 09\u002F01\u002F2022 cannot be determined at this time. Your firm identified its plan to revise its AquaCare Final test Certificate and generate a new Device History Records procedure to meet the requirements of 21 CFR 820.184. The plan may be appropriate based on the documentation provided in the response, but your firm has not completed implementation of the plan, nor documented the plan’s effectiveness. Without this documentation in hand, FDA cannot make an assessment with respect to adequacy.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that your firm’s Velopex AquaCare Dental Abrasion System devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following: failure to submit an MDR report no later than 30 calendar days after the day you receive or otherwise become aware of information that reasonably suggests a marketed device either may have caused or contributed to a death or serious injury, or has malfunctioned and would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur as required by 21 CFR 803.50(a). For example, the information included for your firm’s incident report \u003Cstrong>(b)(4)\u003C\u002Fstrong> reasonably suggests that a patient sustained an injury (i.e., surgical emphysema and an observed area of traumatic ulceration) from your firm’s AquaCare device and subsequently underwent antibiotic treatment. There is no information included in the complaint that rules out that the device may not have caused or contributed to the referenced injury. Further, the information described in the complaint meets the definition of a serious injury under 21 CFR 803.3(w) because medical intervention was necessary to preclude permanent impairment of a body function or permanent damage to a body structure. Your firm became aware of the referenced event on April 12, 2019. However, your firm didn’t submit an MDR for the referenced event.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response dated September 1, 2022, is not adequate. Your response noted that your firm developed an MDR procedure and is in process of establishing an eMDR account for the submission of the referenced report. Based on FDA’s records, your firm had a certificate with Electronic Submissions Gateway (ESG) on August 22, 2022. However, your firm did not complete its load test and guidance compliance submission for eMDR. Your firm should follow the instructions located at How to Enroll in eMDR Program | FDA under step 2 of “Low Volume Enrollment Process” to complete the testing in order to obtain its Web Trader production account. Further, our review concluded that the newly developed MDR procedure is deficient as indicated above and your firm does not plan to take the systemic corrective actions including a retrospective review of complaints for reportability.\u003C\u002Fp>\n\n\u003Cp>Your firm also failed to develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17. For example, during the inspection, your firm identified the documents titled “Vigilance System”, Document \u003Cstrong>(b)(4)\u003C\u002Fstrong>, dated 03\u002F10\u002F2021 and “Vigilance System – Incident Reporting Procedures”, Document \u003Cstrong>(b)(4)\u003C\u002Fstrong>, dated 07\u002F11\u002F2021 as its MDR procedure. However, the procedure does not contain information that would indicate that it is an MDR procedure created in accordance with the requirements of 21 CFR 803.17. Your firm’s response dated September 1, 2022, is not adequate. Your response provided a copy of a newly created MDR procedure titled “Vigilance System – Incident Reporting Procedure in the USA”, Document \u003Cstrong>(b)(4)\u003C\u002Fstrong>, dated 8\u002F1\u002F2022. After reviewing the procedure outlined in your response, the following deficiencies were noted:\u003C\u002Fp>\n\n\u003Cp>a. The procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example, the procedure omits definitions of the terms “malfunction”, “caused or contributed” and “serious injury”. The exclusion of the definitions for these terms from the procedure may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\u003C\u002Fp>\n\n\u003Cp>b. The procedure does not describe how your firm will address documentation and recordkeeping requirements, as required by 21 CFR 803.17(b), including information that was evaluated to determine if an event was reportable. Additionally, the procedure, as written, designates the initial importer Velopex International as the authorized reporter to fulfil the manufacturer’s reporting obligation. Under the MDR regulation, both manufacturers and importers are required to make reports as described in 21 CFR Part803.The section 19(b) of your firm’s procedure states that Velopex International will be required to act as the Manufacturer and will need to report to the FDA directly as required by 21 CFR 803.50 and 803.52. However, this statement does not exempt any mandatory reporting entity from fulfilling its individual reporting requirements.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent by email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2: Establishment Support, Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993. Refer to CMS case #647562 when replying. If you have any questions about the contents of this letter, please contact: Michael Adjodha at (301) 796-6276.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Malvina B. Eydelman, M.D.\u003Cbr>\nDirector\u003Cbr>\nOHT1: Office of Ophthalmic, Anesthesia, Respiratory,\u003Cbr>\nENT and Dental Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>CC:\u003Cbr>\nRegistered Agent Solutions Inc.\u003Cbr>\n1701 Directors Boulevard, Suite 300\u003Cbr>\nAustin, TX 78744\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nMr. Sidney Grant\n\nRecipient Title\n\nManaging Director, CEO\n\nMedivance Instruments Ltd.\n\nBarretts Green Road\n\nHarlesden\n\nLondon\n\nNW10 7AE\n\nUnited Kingdom\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nFebruary 13, 2023\n\nDear Mr. Grant:\n\nDuring an inspection of your firm located in Harlesden, London, United Kingdom on August 8, 2022, through August 11, 2022, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures the Velopex Aquacut Fluid Abrasion Unit (“Velopex Device”) and various accessories as part of the Velopex AquaCare Dental Abrasion line of products. These products are intended for use in a range of dental procedures, including sealant preparation, composite removal and restoration, and cavity preparation. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\n\nWe received a response from you dated September 1, 2022, concerning our investigator’s observations noted on the Form FDA 483 (“FDA 483”), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n\nYour firm currently holds a 510(k) clearance (K024105) for the Velopex Device, which was issued on October 9, 2003. However, since the time it was cleared, the Velopex Device has been, in multiple ways, significantly changed or modified in design, components, method of manufacture, or intended use within the meaning of 21 CFR 807.81(a)(3). Specifically, your firm has made significant changes that include, among other things, the incorporation of a new air regulator and changes to the materials used in the powder tubing\u002Fvalves. Firm documents inspected by FDA noted that the incorporation of a new air regulator is intended to address the risk or reliability and pipe stress failure of the device by changing the parameters of the air flow and operating pressure range that are factory set. The changes to the air regulator may impact the ratio of the air\u002Fwater\u002Fpowder mixture that contacts the surface of the dentition and the efficiency of how that mixture moves through the system. Further, the changed powder tubing\u002Fvalve materials included a container molded insert and slide insider, which may impact the performance of the drip of the powder.\n\nThe changes outlined in this warning letter and other changes could significantly affect the safety or effectiveness of the device within the meaning of 21 CFR 807.81(a)(3). Accordingly, your firm was required to submit a new premarket notification submission under section 510(k) of the Act, 21 U.S.C. § 360(k), to FDA at least 90 days before you proposed to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of the modified Velopex devices (“Modified Velopex Devices”). (See 21 CFR 807.81(a)(3).)\n\nYou did not submit any new 510(k) in association with the Modified Velopex Devices. The Modified Velopex Devices are therefore misbranded under section 502(o) the Act, 21 U.S.C. §352(o), because your firm did not timely notify FDA of its intent to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of the Modified Velopex Devices, as required by section 510(k) of the Act.\n\nOur inspection revealed that the Modified Velopex Devices are also adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g).\n\nFor a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\n\nOur inspection also revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. These deficiencies include, but are not limited to, the following:\n\n1. Failure to establish and maintain procedures for the identification, documentation, validation or where appropriate verification, review and approval of design changes before their implementation as required by 21 CFR 820.30(i). For example, your firm has not verified or validated design changes during and after your firm’s design and development process prior to implementation. Your firm also stated to FDA that certain design changes for your AquaCare devices, including the Aquacut and AquaCare Single and Twin devices, were validated but not adequately documented.\n\nThe response dated 09\u002F01\u002F2022 is not adequate. Your firm identified its plan to revise its Design and Development procedure to meet the requirements of 21 CFR 820.30(i). Also, your firm states it plans to conduct effectiveness checks of these revised procedures. Your firm additionally provided red-lined portions of the current Design and Development procedure to describe the specific changes that were made to the procedure. However, your firm’s response failed to provide a plan on how it would retrospectively validate and, where appropriate, verify that the changes to its 510(k) cleared device were safe and effective for the device’s current intended use. Your response also failed to explain how your firm was going to establish and maintain procedures for the identification, documentation, validation (or, where appropriate, verification), review, and approval of design changes before their implementation on devices currently distributed in the US marketplace.\n\n2. Failure to establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). Your firm failed to conduct CAPA investigations and failed to verify the effectiveness of Corrective Actions taken as part of a CAPA, or indicate that verification was not required, as required by your firm’s corrective and preventive action (CAPA) procedure. For example, your firm’s corrective and preventive action (CAPA) procedure does not have a requirement to verify or validate corrective and\u002For preventive action for every CAPA activity. Upon review of thirty CAPA records from 2019to 2021 (including CAPAs 2019-1 to 2019-5, 2019-7 to 2019-16, 2020-1, 2020-2, and 2021-1 to 2021-13), it was observed that none of these records were evaluated for effectiveness. Further, some CAPA activity lacked corrective and\u002For preventive actions. Accordingly, your firm failed to verify or validate the effectiveness of CAPA actions to ensure the finished device was not adversely affected.\n\nThe response dated 09\u002F01\u002F2022 is not adequate. Your firm identified its plan to revise its CAPA procedure, CAPA Request form and CAPA Log (and provided copies of these revised documents as part of your response) to meet the requirements of 21 CFR 820.100(a). Your firm also noted that staff would be trained on how to implement the updated CAPA procedure, form, and log. However, the firm’s plan did not describe how it planned to address currently outstanding CAPAs, nor provide a timeline on when it anticipated these outstanding CAPAs to be resolved.\n\n3. Failure to review and evaluate all complaints to determine whether an investigation is necessary. When no investigation is made, the manufacturer shall maintain a record that includes the reason no investigation was made and the name of the individual responsible for the decision not to investigate, as required by 21 CFR 820.198(b). For example, your Customer Complaints procedure states all customer complaints must be investigated and if rejected, a justification must be documented. During inspection, your firm stated to FDA that complaint investigations are carried out but might not have been documented. However, forty-eight customer complaints from 2019-2022 were reviewed where no investigation was performed, and a justification was not documented as to why no investigation was performed.\n\nThe response dated 09\u002F01\u002F2022 is not adequate. Your firm identified its plan to revise its Customer Complaints procedure to meet the requirements of 21 CFR 820.198(b). Also, your firm has plans to revise the Customer Complaints Form; generate a new Faults Investigation form and retrain all required personnel. Your firm provided copies of the revised procedure, revised Customer Complaints form and a new Faults Investigation form as part of your investigation. Your firm has yet to complete personnel training. Although your firm’s plan indicates a commitment to resolve new complaints that you receive, it does not address a commitment and timeline to investigate and resolve current, pending complaints such as the ones identified as part of FDA’s investigation. Investigation and resolution of complaints is required per your firm’s revised SOP; which states in part that complaints shall be evaluated to determine whether a CAPA will be required, shall be conducted; and if required the QA\u002FRA department will be notified to coordinate initiation and resolution of the CAPA.\n\n4. Failure to maintain device history records (DHR's). Each manufacturer shall establish and maintain procedures to ensure that DHR's for each batch, lot, or unit are maintained to demonstrate that the device is manufactured in accordance with the device master record(DMR) and the requirements of this part, as required by 21 CFR 820.184. For example, your firm does not have procedures to ensure the DHR for each unit of your device is manufactured in accordance with the DMR and requirements of the regulation. Your firm does not have a DHR procedure. In addition, your firm’s device DHRs for your AquaCare device lacks identification labeling as well as a Unique Device Identifier (UDI) or Universal Product Code (UPC) for each device unit.\n\nThe adequacy of the response dated 09\u002F01\u002F2022 cannot be determined at this time. Your firm identified its plan to revise its AquaCare Final test Certificate and generate a new Device History Records procedure to meet the requirements of 21 CFR 820.184. The plan may be appropriate based on the documentation provided in the response, but your firm has not completed implementation of the plan, nor documented the plan’s effectiveness. Without this documentation in hand, FDA cannot make an assessment with respect to adequacy.\n\nOur inspection also revealed that your firm’s Velopex AquaCare Dental Abrasion System devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following: failure to submit an MDR report no later than 30 calendar days after the day you receive or otherwise become aware of information that reasonably suggests a marketed device either may have caused or contributed to a death or serious injury, or has malfunctioned and would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur as required by 21 CFR 803.50(a). For example, the information included for your firm’s incident report (b)(4) reasonably suggests that a patient sustained an injury (i.e., surgical emphysema and an observed area of traumatic ulceration) from your firm’s AquaCare device and subsequently underwent antibiotic treatment. There is no information included in the complaint that rules out that the device may not have caused or contributed to the referenced injury. Further, the information described in the complaint meets the definition of a serious injury under 21 CFR 803.3(w) because medical intervention was necessary to preclude permanent impairment of a body function or permanent damage to a body structure. Your firm became aware of the referenced event on April 12, 2019. However, your firm didn’t submit an MDR for the referenced event.\n\nYour firm’s response dated September 1, 2022, is not adequate. Your response noted that your firm developed an MDR procedure and is in process of establishing an eMDR account for the submission of the referenced report. Based on FDA’s records, your firm had a certificate with Electronic Submissions Gateway (ESG) on August 22, 2022. However, your firm did not complete its load test and guidance compliance submission for eMDR. Your firm should follow the instructions located at How to Enroll in eMDR Program | FDA under step 2 of “Low Volume Enrollment Process” to complete the testing in order to obtain its Web Trader production account. Further, our review concluded that the newly developed MDR procedure is deficient as indicated above and your firm does not plan to take the systemic corrective actions including a retrospective review of complaints for reportability.\n\nYour firm also failed to develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17. For example, during the inspection, your firm identified the documents titled “Vigilance System”, Document (b)(4), dated 03\u002F10\u002F2021 and “Vigilance System – Incident Reporting Procedures”, Document (b)(4), dated 07\u002F11\u002F2021 as its MDR procedure. However, the procedure does not contain information that would indicate that it is an MDR procedure created in accordance with the requirements of 21 CFR 803.17. Your firm’s response dated September 1, 2022, is not adequate. Your response provided a copy of a newly created MDR procedure titled “Vigilance System – Incident Reporting Procedure in the USA”, Document (b)(4), dated 8\u002F1\u002F2022. After reviewing the procedure outlined in your response, the following deficiencies were noted:\n\na. The procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example, the procedure omits definitions of the terms “malfunction”, “caused or contributed” and “serious injury”. The exclusion of the definitions for these terms from the procedure may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\n\nb. The procedure does not describe how your firm will address documentation and recordkeeping requirements, as required by 21 CFR 803.17(b), including information that was evaluated to determine if an event was reportable. Additionally, the procedure, as written, designates the initial importer Velopex International as the authorized reporter to fulfil the manufacturer’s reporting obligation. Under the MDR regulation, both manufacturers and importers are required to make reports as described in 21 CFR Part803.The section 19(b) of your firm’s procedure states that Velopex International will be required to act as the Manufacturer and will need to report to the FDA directly as required by 21 CFR 803.50 and 803.52. However, this statement does not exempt any mandatory reporting entity from fulfilling its individual reporting requirements.\n\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent by email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2: Establishment Support, Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993. Refer to CMS case #647562 when replying. If you have any questions about the contents of this letter, please contact: Michael Adjodha at (301) 796-6276.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely yours,\n\n\u002FS\u002F\n\nMalvina B. Eydelman, M.D.\n\nDirector\n\nOHT1: Office of Ophthalmic, Anesthesia, Respiratory,\n\nENT and Dental Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\nCC:\n\nRegistered Agent Solutions Inc.\n\n1701 Directors Boulevard, Suite 300\n\nAustin, TX 78744","Medivance Instruments Ltd.","medivance-instruments-ltd-647562-02132023","2026-08-18T06:42:29.145918+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmedivance-instruments-ltd-647562-02132023","2026-10-26T08:09:23.334631+00:00","Warning Letter","Issued","2023-04-25","647562","Medical Devices","Mr. Sidney Grant","2026-08-20T01:08:27.03+00:00","2023-02-13",{"id":32,"raw":33,"subject":40,"body_html":41,"body_text":42,"firm_name":43,"letter_id":44,"created_at":45,"fei_number":20,"letter_url":46,"updated_at":47,"action_type":23,"case_status":48,"posted_date":49,"marcs_cms_no":50,"product_type":51,"closeout_date":52,"issuing_office":37,"recipient_name":53,"body_fetched_at":54,"delivery_method":55,"recipient_title":20,"reference_number":20,"action_taken_date":56,"medical_device_id":20,"response_letter_date":20},909,[34,35,36,37,38,13,39,13],"\u003Ctime datetime=\"2025-05-13T04:00:00Z\">05\u002F13\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-04-08T04:00:00Z\">04\u002F08\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftailstorm-health-inc-dba-medivant-health-703497-04082025\">Tailstorm Health Inc. dba Medivant Health\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","Compounding Pharmacy\u002FAdulterated Drug Products \u003Cbr \u002F>\r\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftailstorm-health-inc-dba-medivant-health-703497-03232026\">\u003Ctime datetime=\"2026-04-14T04:00:00Z\">04\u002F14\u002F2026\u003C\u002Ftime>\n\u003C\u002Fa>","Compounding Pharmacy\u002FAdulterated Drug Products","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Electronic Mail - Delivery and Read Receipt Requested\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Viraj Gandhi\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Tailstorm Health Inc. dba Medivant Health\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>24416 N. 19th Avenue Suite 200\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Phoenix\u003C\u002Fspan>, \u003Cspan>AZ\u003C\u002Fspan> \u003Cspan>85085-1400\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>\u003Cstrong>WL # 703497\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>April 8, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Gandhi:\u003C\u002Fp>\u003Cp>You registered your facility with the U.S. Food and Drug Administration (FDA) as an outsourcing facility under section 503B of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. § 353b]\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> on October 23, 2019, and most recently on December 18, 2024. From September 24, 2024, to October 10, 2024, an FDA investigator inspected your facility, Tailstorm Health Inc. dba Medivant Health located at 24416 N. 19th Avenue Suite 200, Phoenix, AZ 85085. During the inspection, the investigator collected evidence that drug products you produced failed to meet the conditions of section 503B of the FDCA necessary for drugs produced by an outsourcing facility to qualify for exemptions from certain provisions of the FDCA. In addition, the investigator noted serious deficiencies in your practices for producing drug products intended or expected to be sterile, which put patients at risk.\u003C\u002Fp>\u003Cp>FDA issued a Form FDA 483 and an amended Form FDA 483 to your facility on October 10, 2024. FDA acknowledges receipt of your facility’s responses, dated October 31, 2024, December 9, 2024, and January 23, 2025. FDA also acknowledges that on November 6, 2024, your firm initiated a voluntary recall of lots D24005, D24006, D24007, D24008, D24009, and D24012 of Bevacizumab (Avastin) 1.25mg\u002F0.05mL, 0.5 mL Single-Dose Syringe, intended or expected to be sterile, within expiry, due to lack of sterility assurance. Based on this inspection, it appears you produced drugs that violate the FDCA.\u003C\u002Fp>\u003Cp>\u003Cstrong>A. Compounded Drug Products under the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Under section 503B(b) of the FDCA, a compounder can register as an outsourcing facility with FDA. Drug products compounded by or under the direct supervision of a licensed pharmacist in an outsourcing facility qualify for exemptions from the drug approval requirements in section 505 of the FDCA [21 U.S.C. § 355(a)], the requirement in section 502(f)(1) of the FDCA [21 U.S.C. § 352(f)(1)] that labeling bear adequate directions for use and the Drug Supply Chain Security Act requirements in section 582 of the FDCA [21 U.S.C. § 360eee-1] if the conditions in section 503B of the FDCA are met.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>An outsourcing facility, which is defined in section 503B(d)(4) of the FDCA [21 U.S.C. § 353b(d)(4)], is a facility at one geographic location or address that — (i) is engaged in the compounding of sterile drugs; (ii) has elected to register as an outsourcing facility; and (iii) complies with all of the requirements of this section. Outsourcing facilities must comply with other applicable provisions of the FDCA, including section 501(a)(2)(B) [21 U.S.C. § 351(a)(2)(B)], regarding current good manufacturing practice (CGMP), and section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)], regarding insanitary conditions. Generally, CGMP requirements for the preparation of drug products are established in Title 21 of the Code of Federal Regulations (CFR) parts 210 and 211.\u003C\u002Fp>\u003Cp>In addition, for a compounded drug product to qualify for the exemptions under section 503B, the labeling of the drug must include certain information (section 503B(a)(10) of the FDCA [21 U.S.C. § 353b(a)(10)]).\u003C\u002Fp>\u003Cp>Furthermore, for a compounded drug product to qualify for the exemptions under section 503B, it must be compounded in an outsourcing facility that is in compliance with the registration and reporting requirements in section 503B(b), including the requirement to submit adverse event reports to FDA “in accordance with the content and format requirements established through guidance or regulation under section 310.305 of title 21, Code of Federal Regulations (or any successor regulations)” (section 503B(a)(1), (b)(5) of the FDCA [21 U.S.C. § 353b(a)(1), (b)(5)]).\u003C\u002Fp>\u003Cp>\u003Cstrong>B. Failure to Meet the Conditions of Section 503B\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>During the inspection, the FDA investigator noted that drug products produced by your facility failed to meet the conditions of section 503B. For example, the investigator collected evidence that:\u003C\u002Fp>\u003Cp>1. Your facility’s drug products, such as Semaglutide Injection 1mg\u002F0.2ml and Tirzepatide Injection 2.5mg\u002F0.5ml, did not include the following on the label: “Office Use Only.”\u003C\u002Fp>\u003Cp>2. Your facility did not submit adverse event reports to FDA in accordance with the content and format requirements established through guidance or regulation under section 310.305 of title 21, Code of Federal Regulations (or any successor regulations). Specifically, your facility’s procedures for reporting adverse events are inadequate. For example, your documented procedures for reporting adverse events do not describe an adverse event as “unexpected” when one is not listed in the current labeling for the drug product (21 CFR 310.305(b) and do not provide that adverse events should be reported utilizing FDA’s Safety Reporting Portal (SRP) or Electronic Submission Gateway (ESG) (21 CFR 310.305(e)).\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Because your compounded drug products have not met all of the conditions of section 503B, they are not eligible for the exemptions in that section from the FDA approval requirements of section 505, the requirement under section 502(f)(1) that labeling bear adequate directions for use, and the Drug Supply Chain Security Act requirements described in section 582 of the FDCA.\u003C\u002Fp>\u003Cp>Specific violations are described below.\u003C\u002Fp>\u003Cp>\u003Cstrong>C. Violations of the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Adulterated Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The FDA investigator noted that drug products intended or expected to be sterile were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, causing your drug products to be adulterated under section 501(a)(2)(A) of the FDCA. For example, the investigator observed that:\u003C\u002Fp>\u003Cp>1. You did not perform adequate product evaluation and take appropriate corrective action after microbial contamination was recovered within the ISO 5 aseptic processing area.\u003C\u002Fp>\u003Cp>2. Your firm failed to perform adequate smoke studies under dynamic conditions to demonstrate unidirectional airflow within the ISO 5 area. Therefore, your products intended to be sterile are produced in an environment that may not provide adequate protection against the risk of contamination.\u003C\u002Fp>\u003Cp>The FDA investigator also noted CGMP violations at your facility, that caused your drug products to be adulterated within the meaning of section 501(a)(2)(B) of the FDCA. The violations include, for example:\u003C\u002Fp>\u003Cp>1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fp>\u003Cp>2. Your firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas (21 CFR 211.42(c)(10)(iv)).\u003C\u002Fp>\u003Cp>Outsourcing facilities must comply with CGMP requirements under section 501(a)(2)(B) of the FDCA. FDA’s regulations regarding CGMP requirements for the preparation of drug products have been established in 21 CFR parts 210 and 211. FDA intends to promulgate more specific CGMP regulations for outsourcing facilities. FDA has issued a revised draft guidance, \u003Cem>Current Good Manufacturing Practice — Guidance for Human Drug Compounding Outsourcing Facilities under Section 503B of the FD&amp;C Act\u003C\u002Fem>. This draft guidance, when finalized, will describe FDA’s expectations regarding outsourcing facilities and the CGMP requirements in 21 CFR parts 210 and 211 until more specific CGMP regulations for outsourcing facilities are promulgated.\u003C\u002Fp>\u003Cp>Under section 301(a) of the FDCA [21 U.S.C. § 331(a), the introduction or delivery for introduction into interstate commerce of any drug that is adulterated is a prohibited act. Further, it is a prohibited act under section 301(k) of the FDCA [21 U.S.C. § 331(k)] to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being adulterated.\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved New Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You do not have any FDA-approved applications on file for drug products that you compound.\u003Cem>\u003Cstrong>\u003Csup>4\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Under sections 505(a) and 301(d) of the FDCA [21 U.S.C. §§ 331(d)] a new drug may not be introduced into or delivered for introduction into interstate commerce unless an application approved by FDA under section 505 of the FDCA is in effect for the drug. Marketing of these products, or other applicable products, without an approved application violates these provisions of the FDCA.\u003C\u002Fp>\u003Cp>\u003Cstrong>Misbranded Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You compound drug products that are intended for conditions not amenable to self-diagnosis and treatment by individuals who are not medical practitioners; therefore, adequate directions for use cannot be written so that a layman can use these products safely for their intended uses. Consequently, their labeling fails to bear adequate directions for their intended uses causing them to be misbranded under section 502(f)(1) of the FDCA.\u003Cem>\u003Cstrong>\u003Csup>5\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> The introduction or delivery for introduction into interstate commerce of these products therefore violates section 301(a) of the FDCA. Further, it is also a prohibited act under section 301(k) of the FDCA to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being misbranded.\u003C\u002Fp>\u003Cp>\u003Cstrong>D. Corrective Actions\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We have reviewed your facility’s responses to the Form FDA 483. We also acknowledge your recall of lots D24005, D24006, D24007, D24008, D24009, and D24012 of repackaged Bevacizumab (Avastin) 1.25mg\u002F0.05mL, 0.5 mL Single-Dose Syringe, intended or expected to be sterile, within expiry, due to lack of sterility assurance.\u003C\u002Fp>\u003Cp>Regarding your responses related to the insanitary conditions and CGMP violations, some of your proposed corrective actions appear adequate; however, we are unable to fully evaluate some of your corrective actions due to lack of adequate supporting documentation:\u003C\u002Fp>\u003Cp>1. Regarding particulate matter testing of your finished drug products:\u003C\u002Fp>\u003Cp>a. We have reviewed your document titled, “Retrospective Review Investigation of Reported OOS incidents (1B).” Within that document, you state, “Tailstorm has researched the product Avastin, which contains Bevacizumab, a protein that may interfere with liquid-borne particle count testing. The nature of the product can lead to inconsistent results when tested microscopically using Method \u003Cstrong>(b)(4)\u003C\u002Fstrong>.” You also stated that, “The test method and procedure were found to involve many physical maneuvers” and that, “the preliminary sample preparation steps are not protected under a bio-safety cabinet\u002FLAF (laminar air flow).” Despite these concerns, your firm relied on passing results via method \u003Cstrong>(b)(4)\u003C\u002Fstrong> to release lots D24006, D24007, and D24009.\u003C\u002Fp>\u003Cp>b. Your response did not address the approval process for changes occurring at your contract testing facility. FDA is aware that many drug manufacturers use independent contractors such as testing laboratories. FDA regards contractors as extensions of the manufacturer. You are responsible for the quality of your drugs regardless of agreements in place with your contract facility. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fcontract-manufacturing-arrangements-drugs-quality-agreements-guidance-industry.\u003C\u002Fp>\u003Cp>c. For Bevacizumab lot D24008, your investigation identified elastomer\u002Frubber particles and noted, “source is syringe stopper or syringe cap rubber seal.” However, you did not provide the actions you took to correct and prevent the recurrence of these particles. Your action plans should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, corrective action and preventive action (CAPA) effectiveness, and quality assurance oversight.\u003C\u002Fp>\u003Cp>Some of your corrective actions appear deficient:\u003C\u002Fp>\u003Cp>1. Regarding your updated smoke studies provided in your response:\u003C\u002Fp>\u003Cp>a. The dynamic smoke study in your video titled “Removal of \u003Cstrong>(b)(4)\u003C\u002Fstrong> layer from the tub” under file name “Act 21” does not show smoke in the area in which the open tub of what appears to be product syringes is moved during time 00:51 to 00:58. This same area shows air turbulence during your static smoke study video “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Removal” under file name “Act \u003Cstrong>(b)(4)\u003C\u002Fstrong>” during time \u003Cstrong>(b)(4)\u003C\u002Fstrong>.&nbsp;\u003C\u002Fp>\u003Cp>b. The smoke study in your video titled “Replacement of Needle (Open door)” under file name “Act 44” does not appear to encompass all areas within the ISO 5 \u003Cstrong>(b)(4)\u003C\u002Fstrong> including but not limited to the interventions performed by the operator during needle replacement.\u003C\u002Fp>\u003Cp>2. Regarding your personnel monitoring program, we have reviewed your provided evaluation and acknowledge your statement that, “the practice of breaking first air with the head and chest during open \u003Cstrong>(b)(4)\u003C\u002Fstrong> doors interventions has been remediated.” We also acknowledge that you have updated your SOP to “add personnel monitoring sample sites of the right shoulder and left shoulder for the machine assembly process.” However, in our review of your updated smoke study titled “Act 15” it appears that your operator’s head and goggles enter the ISO 5 space within the \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>In addition to the issues discussed above, you should note that CGMP requires the implementation of quality oversight and controls over the manufacture of drugs, including the safety of raw materials, materials used in drug manufacturing, and finished drug products. See section 501 of the FDCA. If you choose to contract with a laboratory to perform some functions required by CGMP, it is essential that you select a qualified contractor and that you maintain sufficient oversight of the contractor’s operations to ensure that it is fully CGMP compliant. Regardless of whether you rely on a contract facility, you are responsible for assuring that drugs you produce are neither adulterated nor misbranded. [\u003Cem>See\u003C\u002Fem> 21 CFR 210.1(b), 21 CFR 200.10(b).]\u003C\u002Fp>\u003Cp>In addition, regarding issues related to the conditions of section 503B of the FDCA, some of your corrective actions appear adequate: You state that you have “revised the affected labels to include the necessary statements and enhance the label review and approval process to ensure compliance with all regulatory standards in the future.”\u003C\u002Fp>\u003Cp>You did not address certain issues related to the conditions of section 503B of the FDCA. More specifically, your SOP for adverse event reporting does not adequately address adverse event reporting. For example, your procedures do not adequately define what constitutes an “unexpected” adverse event and your procedures do not provide that adverse events should be reported utilizing the Safety Reporting Portal (SRP) or Electronic Submission Gateway (ESG).\u003C\u002Fp>\u003Cp>Should you continue to compound and distribute drug products that do not meet the conditions of section 503B, the compounding and distribution of your drugs would be subject to the new drug approval requirement, the requirement to label drug products with adequate directions for use, and the Drug Supply Chain Security Act requirements.\u003C\u002Fp>\u003Cp>FDA strongly recommends that your management undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems. In particular, this review should assess your aseptic processing operations. A third party consultant with relevant sterile drug manufacturing expertise should assist you in conducting this comprehensive evaluation.\u003C\u002Fp>\u003Cp>\u003Cstrong>E. Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive statement of violations at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>You should take prompt action to address any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Within fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\u003Cp>All correspondence should refer to the Warning Letter Number above (# 703497) and include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>F. Gail Bormel, JD, RPh\u003Cbr>Director\u003Cbr>Office of Compounding Quality and Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>___________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> See Pub. L. No. 113-54, § 102(a), 127 Stat. 587, 587-588 (2013).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> We remind you that there are conditions, other than those discussed in this letter, that must be satisfied to qualify for the exemptions in section 503B of the FDCA.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> For more information, see, FDA’s guidance, “Adverse Event Reporting for Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act,” which can be found at https:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidanceComplianceRegulatoryInformation\u002FGuidances\u002FUCM434188.pdf.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> The specific products made by your firm are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> Your compounded drug products are not exempted from the requirements of section 502(f)(1) of the FDCA by regulations issued by the FDA (see, e.g., 21 CFR 201.115).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Electronic Mail - Delivery and Read Receipt Requested\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nViraj Gandhi\n\nRecipient Title\n\nCEO\n\nTailstorm Health Inc. dba Medivant Health\n\n24416 N. 19th Avenue Suite 200\n\nPhoenix, AZ 85085-1400\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nWL # 703497\nApril 8, 2025\nDear Mr. Gandhi:\nYou registered your facility with the U.S. Food and Drug Administration (FDA) as an outsourcing facility under section 503B of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. § 353b]1 on October 23, 2019, and most recently on December 18, 2024. From September 24, 2024, to October 10, 2024, an FDA investigator inspected your facility, Tailstorm Health Inc. dba Medivant Health located at 24416 N. 19th Avenue Suite 200, Phoenix, AZ 85085. During the inspection, the investigator collected evidence that drug products you produced failed to meet the conditions of section 503B of the FDCA necessary for drugs produced by an outsourcing facility to qualify for exemptions from certain provisions of the FDCA. In addition, the investigator noted serious deficiencies in your practices for producing drug products intended or expected to be sterile, which put patients at risk.\nFDA issued a Form FDA 483 and an amended Form FDA 483 to your facility on October 10, 2024. FDA acknowledges receipt of your facility’s responses, dated October 31, 2024, December 9, 2024, and January 23, 2025. FDA also acknowledges that on November 6, 2024, your firm initiated a voluntary recall of lots D24005, D24006, D24007, D24008, D24009, and D24012 of Bevacizumab (Avastin) 1.25mg\u002F0.05mL, 0.5 mL Single-Dose Syringe, intended or expected to be sterile, within expiry, due to lack of sterility assurance. Based on this inspection, it appears you produced drugs that violate the FDCA.\nA. Compounded Drug Products under the FDCA\nUnder section 503B(b) of the FDCA, a compounder can register as an outsourcing facility with FDA. Drug products compounded by or under the direct supervision of a licensed pharmacist in an outsourcing facility qualify for exemptions from the drug approval requirements in section 505 of the FDCA [21 U.S.C. § 355(a)], the requirement in section 502(f)(1) of the FDCA [21 U.S.C. § 352(f)(1)] that labeling bear adequate directions for use and the Drug Supply Chain Security Act requirements in section 582 of the FDCA [21 U.S.C. § 360eee-1] if the conditions in section 503B of the FDCA are met.2\nAn outsourcing facility, which is defined in section 503B(d)(4) of the FDCA [21 U.S.C. § 353b(d)(4)], is a facility at one geographic location or address that — (i) is engaged in the compounding of sterile drugs; (ii) has elected to register as an outsourcing facility; and (iii) complies with all of the requirements of this section. Outsourcing facilities must comply with other applicable provisions of the FDCA, including section 501(a)(2)(B) [21 U.S.C. § 351(a)(2)(B)], regarding current good manufacturing practice (CGMP), and section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)], regarding insanitary conditions. Generally, CGMP requirements for the preparation of drug products are established in Title 21 of the Code of Federal Regulations (CFR) parts 210 and 211.\nIn addition, for a compounded drug product to qualify for the exemptions under section 503B, the labeling of the drug must include certain information (section 503B(a)(10) of the FDCA [21 U.S.C. § 353b(a)(10)]).\nFurthermore, for a compounded drug product to qualify for the exemptions under section 503B, it must be compounded in an outsourcing facility that is in compliance with the registration and reporting requirements in section 503B(b), including the requirement to submit adverse event reports to FDA “in accordance with the content and format requirements established through guidance or regulation under section 310.305 of title 21, Code of Federal Regulations (or any successor regulations)” (section 503B(a)(1), (b)(5) of the FDCA [21 U.S.C. § 353b(a)(1), (b)(5)]).\nB. Failure to Meet the Conditions of Section 503B\nDuring the inspection, the FDA investigator noted that drug products produced by your facility failed to meet the conditions of section 503B. For example, the investigator collected evidence that:\n1. Your facility’s drug products, such as Semaglutide Injection 1mg\u002F0.2ml and Tirzepatide Injection 2.5mg\u002F0.5ml, did not include the following on the label: “Office Use Only.”\n2. Your facility did not submit adverse event reports to FDA in accordance with the content and format requirements established through guidance or regulation under section 310.305 of title 21, Code of Federal Regulations (or any successor regulations). Specifically, your facility’s procedures for reporting adverse events are inadequate. For example, your documented procedures for reporting adverse events do not describe an adverse event as “unexpected” when one is not listed in the current labeling for the drug product (21 CFR 310.305(b) and do not provide that adverse events should be reported utilizing FDA’s Safety Reporting Portal (SRP) or Electronic Submission Gateway (ESG) (21 CFR 310.305(e)).3\nBecause your compounded drug products have not met all of the conditions of section 503B, they are not eligible for the exemptions in that section from the FDA approval requirements of section 505, the requirement under section 502(f)(1) that labeling bear adequate directions for use, and the Drug Supply Chain Security Act requirements described in section 582 of the FDCA.\nSpecific violations are described below.\nC. Violations of the FDCA\nAdulterated Drug Products\nThe FDA investigator noted that drug products intended or expected to be sterile were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, causing your drug products to be adulterated under section 501(a)(2)(A) of the FDCA. For example, the investigator observed that:\n1. You did not perform adequate product evaluation and take appropriate corrective action after microbial contamination was recovered within the ISO 5 aseptic processing area.\n2. Your firm failed to perform adequate smoke studies under dynamic conditions to demonstrate unidirectional airflow within the ISO 5 area. Therefore, your products intended to be sterile are produced in an environment that may not provide adequate protection against the risk of contamination.\nThe FDA investigator also noted CGMP violations at your facility, that caused your drug products to be adulterated within the meaning of section 501(a)(2)(B) of the FDCA. The violations include, for example:\n1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\n2. Your firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas (21 CFR 211.42(c)(10)(iv)).\nOutsourcing facilities must comply with CGMP requirements under section 501(a)(2)(B) of the FDCA. FDA’s regulations regarding CGMP requirements for the preparation of drug products have been established in 21 CFR parts 210 and 211. FDA intends to promulgate more specific CGMP regulations for outsourcing facilities. FDA has issued a revised draft guidance, Current Good Manufacturing Practice — Guidance for Human Drug Compounding Outsourcing Facilities under Section 503B of the FD&C Act. This draft guidance, when finalized, will describe FDA’s expectations regarding outsourcing facilities and the CGMP requirements in 21 CFR parts 210 and 211 until more specific CGMP regulations for outsourcing facilities are promulgated.\nUnder section 301(a) of the FDCA [21 U.S.C. § 331(a), the introduction or delivery for introduction into interstate commerce of any drug that is adulterated is a prohibited act. Further, it is a prohibited act under section 301(k) of the FDCA [21 U.S.C. § 331(k)] to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being adulterated.\nUnapproved New Drug Products\nYou do not have any FDA-approved applications on file for drug products that you compound.4 Under sections 505(a) and 301(d) of the FDCA [21 U.S.C. §§ 331(d)] a new drug may not be introduced into or delivered for introduction into interstate commerce unless an application approved by FDA under section 505 of the FDCA is in effect for the drug. Marketing of these products, or other applicable products, without an approved application violates these provisions of the FDCA.\nMisbranded Drug Products\nYou compound drug products that are intended for conditions not amenable to self-diagnosis and treatment by individuals who are not medical practitioners; therefore, adequate directions for use cannot be written so that a layman can use these products safely for their intended uses. Consequently, their labeling fails to bear adequate directions for their intended uses causing them to be misbranded under section 502(f)(1) of the FDCA.5 The introduction or delivery for introduction into interstate commerce of these products therefore violates section 301(a) of the FDCA. Further, it is also a prohibited act under section 301(k) of the FDCA to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being misbranded.\nD. Corrective Actions\nWe have reviewed your facility’s responses to the Form FDA 483. We also acknowledge your recall of lots D24005, D24006, D24007, D24008, D24009, and D24012 of repackaged Bevacizumab (Avastin) 1.25mg\u002F0.05mL, 0.5 mL Single-Dose Syringe, intended or expected to be sterile, within expiry, due to lack of sterility assurance.\nRegarding your responses related to the insanitary conditions and CGMP violations, some of your proposed corrective actions appear adequate; however, we are unable to fully evaluate some of your corrective actions due to lack of adequate supporting documentation:\n1. Regarding particulate matter testing of your finished drug products:\na. We have reviewed your document titled, “Retrospective Review Investigation of Reported OOS incidents (1B).” Within that document, you state, “Tailstorm has researched the product Avastin, which contains Bevacizumab, a protein that may interfere with liquid-borne particle count testing. The nature of the product can lead to inconsistent results when tested microscopically using Method (b)(4).” You also stated that, “The test method and procedure were found to involve many physical maneuvers” and that, “the preliminary sample preparation steps are not protected under a bio-safety cabinet\u002FLAF (laminar air flow).” Despite these concerns, your firm relied on passing results via method (b)(4) to release lots D24006, D24007, and D24009.\nb. Your response did not address the approval process for changes occurring at your contract testing facility. FDA is aware that many drug manufacturers use independent contractors such as testing laboratories. FDA regards contractors as extensions of the manufacturer. You are responsible for the quality of your drugs regardless of agreements in place with your contract facility. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fcontract-manufacturing-arrangements-drugs-quality-agreements-guidance-industry.\nc. For Bevacizumab lot D24008, your investigation identified elastomer\u002Frubber particles and noted, “source is syringe stopper or syringe cap rubber seal.” However, you did not provide the actions you took to correct and prevent the recurrence of these particles. Your action plans should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, corrective action and preventive action (CAPA) effectiveness, and quality assurance oversight.\nSome of your corrective actions appear deficient:\n1. Regarding your updated smoke studies provided in your response:\na. The dynamic smoke study in your video titled “Removal of (b)(4) layer from the tub” under file name “Act 21” does not show smoke in the area in which the open tub of what appears to be product syringes is moved during time 00:51 to 00:58. This same area shows air turbulence during your static smoke study video “(b)(4) Removal” under file name “Act (b)(4)” during time (b)(4).\nb. The smoke study in your video titled “Replacement of Needle (Open door)” under file name “Act 44” does not appear to encompass all areas within the ISO 5 (b)(4) including but not limited to the interventions performed by the operator during needle replacement.\n2. Regarding your personnel monitoring program, we have reviewed your provided evaluation and acknowledge your statement that, “the practice of breaking first air with the head and chest during open (b)(4) doors interventions has been remediated.” We also acknowledge that you have updated your SOP to “add personnel monitoring sample sites of the right shoulder and left shoulder for the machine assembly process.” However, in our review of your updated smoke study titled “Act 15” it appears that your operator’s head and goggles enter the ISO 5 space within the (b)(4).\nIn addition to the issues discussed above, you should note that CGMP requires the implementation of quality oversight and controls over the manufacture of drugs, including the safety of raw materials, materials used in drug manufacturing, and finished drug products. See section 501 of the FDCA. If you choose to contract with a laboratory to perform some functions required by CGMP, it is essential that you select a qualified contractor and that you maintain sufficient oversight of the contractor’s operations to ensure that it is fully CGMP compliant. Regardless of whether you rely on a contract facility, you are responsible for assuring that drugs you produce are neither adulterated nor misbranded. [See 21 CFR 210.1(b), 21 CFR 200.10(b).]\nIn addition, regarding issues related to the conditions of section 503B of the FDCA, some of your corrective actions appear adequate: You state that you have “revised the affected labels to include the necessary statements and enhance the label review and approval process to ensure compliance with all regulatory standards in the future.”\nYou did not address certain issues related to the conditions of section 503B of the FDCA. More specifically, your SOP for adverse event reporting does not adequately address adverse event reporting. For example, your procedures do not adequately define what constitutes an “unexpected” adverse event and your procedures do not provide that adverse events should be reported utilizing the Safety Reporting Portal (SRP) or Electronic Submission Gateway (ESG).\nShould you continue to compound and distribute drug products that do not meet the conditions of section 503B, the compounding and distribution of your drugs would be subject to the new drug approval requirement, the requirement to label drug products with adequate directions for use, and the Drug Supply Chain Security Act requirements.\nFDA strongly recommends that your management undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems. In particular, this review should assess your aseptic processing operations. A third party consultant with relevant sterile drug manufacturing expertise should assist you in conducting this comprehensive evaluation.\nE. Conclusion\nThe violations cited in this letter are not intended to be an all-inclusive statement of violations at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nYou should take prompt action to address any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\nWithin fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\nAll correspondence should refer to the Warning Letter Number above (# 703497) and include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nF. Gail Bormel, JD, RPh\nDirector\nOffice of Compounding Quality and Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\n___________________\n1 See Pub. L. No. 113-54, § 102(a), 127 Stat. 587, 587-588 (2013).\n2 We remind you that there are conditions, other than those discussed in this letter, that must be satisfied to qualify for the exemptions in section 503B of the FDCA.\n3 For more information, see, FDA’s guidance, “Adverse Event Reporting for Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act,” which can be found at https:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidanceComplianceRegulatoryInformation\u002FGuidances\u002FUCM434188.pdf.\n4 The specific products made by your firm are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\n5 Your compounded drug products are not exempted from the requirements of section 502(f)(1) of the FDCA by regulations issued by the FDA (see, e.g., 21 CFR 201.115).","Tailstorm Health Inc. dba Medivant Health","tailstorm-health-inc-dba-medivant-health-703497-04082025","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftailstorm-health-inc-dba-medivant-health-703497-04082025","2026-10-26T08:10:09.502337+00:00","Closed Out","2025-05-13","703497","Drugs","2026-04-14","Viraj Gandhi","2026-08-19T16:48:20.251+00:00","Via Electronic Mail - Delivery and Read Receipt Requested","2025-04-08",2,{"510k":59,"classification":60,"enforcement":61,"event":62,"event_backfill":63,"pma":64,"warning_letter":65},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]